Case Study: World’s Biggest Pharmaceutical Brand achieves clinical-data ecosystem convergence and major cost savings with GEP

How GEP Helped a Global Pharma Giant Drive Synergies Through Post-Merger Clinical Data Ecosystem Integration

A Fortune 100 pharmaceutical company engaged GEP after a record‑breaking M&A to converge and rationalize its clinical trial data ecosystems amid COVID‑related uncertainty, tight timelines and growing trial backlogs. The merger had left multiple overlapping software programs, gaps in license consumption data and high switching costs, creating significant risk to trial continuity, costs and timelines.

GEP conducted a deep dive on 100+ agreements, analyzed multi‑source trial and CRO data, ran stakeholder workshops and scenario modeling, and led fact‑based supplier negotiations. The program delivered ~7% savings on annual licensing, ~30% savings on managed services, a ~$200M multiyear contract with clearer, fixed pricing (removing cost‑of‑living adjustments) and a redesigned governance model for faster decision‑making and stronger supplier management.